Just sharing an ASH medical journal study of CLL patient’s responses to the Pfizer Covid vaccine:
Among patients with chronic lymphocytic leukemia (CLL, n = 169) who received two doses of the Pfizer-BioNTech vaccine, the antibody response rate was 39.5% as measured by the Elecsys Anti-SARS-CoV-2 assay at a median of 15 days after the second dose. Compared to age- and sex-matched controls, the response rate among patients with CLL was significantly reduced (aOR =0.01). The response rate was highest in patients who were in remission after treatment (79.2%), followed by 55.2% in treatment-naïve and 16% in patients undergoing treatment at the time of vaccination. In patients treated with either Bruton tyrosine kinase inhibitors or venetoclax with or without anti-CD20 antibody, response rates were low (16.0% and 13.6%, respectively):
To date this study from Tel Aviv is the reference for anyone interested in how CLL patients respond to vaccination against Covid19. It's the only one to yield grouped results for CLL patients at different stages of disease and treatment. The researchers plan to look at cellular immune responses too.
My hunch is that this study is essentially right and that larger studies ongoing in the US and the UK will just add more detail.
I'm not sure of the reliability of these results. However, I am part of the CLL / Ibrutinib study at NIH and I intend to ask my NIH doctors about the effectiveness of the Phizer vaccine for those like me who have CLL. My next appointment at NIH is in early July. I'll post here whatever information they provide me.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.